Hemogenyx Pharmaceuticals Insider Buyers See Boost After Market Cap Rose UK£8.3m

Insiders who bought Hemogenyx Pharmaceuticals Plc (LON:HEMO) stock in the last 12 months were richly rewarded last week. The company's market value increased by UK£8.3m as a result of the stock's 103% gain over the same period. As a result, the stock they originally bought for UK£451.2k is now worth UK£862.5k.

Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

The Last 12 Months Of Insider Transactions At Hemogenyx Pharmaceuticals

The Co-Founder Vladislav Sandler made the biggest insider purchase in the last 12 months. That single transaction was for UK£451k worth of shares at a price of UK£1.80 each. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of UK£3.45. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

See our latest analysis for Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Insider Ownership

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data indicates that Hemogenyx Pharmaceuticals insiders own about UK£1.1m worth of shares (which is 6.5% of the company). We do generally prefer see higher levels of insider ownership.

So What Does This Data Suggest About Hemogenyx Pharmaceuticals Insiders?

There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. We'd like to see bigger individual holdings. However, we don't see anything to make us think Hemogenyx Pharmaceuticals insiders are doubting the company. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. At Simply Wall St, we've found that Hemogenyx Pharmaceuticals has 5 warning signs (4 are significant!) that deserve your attention before going any further with your analysis.

But note: Hemogenyx Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.